<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38269049</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Convalescent Plasma Therapy: Long-term Implications.</ArticleTitle><Pagination><StartPage>ofad686</StartPage><MedlinePgn>ofad686</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad686</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad686</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The long-term effect of coronavirus disease 2019 (COVID-19) acute treatments on postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) is unknown. The CONTAIN-Extend study explores the long-term impact of COVID-19 convalescent plasma (CCP) therapy on postacute sequelae of SARS-CoV-2 infection (PASC) symptoms and general health 18 months following hospitalization.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The CONTAIN-Extend study examined 281 participants from the original CONTAIN COVID-19 trial (CONTAIN-RCT, NCT04364737) at 18 months post-hospitalization for acute COVID-19. Symptom surveys, global health assessments, and biospecimen collection were performed from November 2021 to October 2022. Multivariable logistic and linear regression estimated associations between the randomization arms and self-reported symptoms and Patient-Reported Outcomes Measurement Information System (PROMIS) scores and adjusted for covariables, including age, sex, race/ethnicity, disease severity, and CONTAIN enrollment quarter and sites.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were no differences in symptoms or PROMIS scores between CCP and placebo (adjusted odds ratio [aOR] of general symptoms, 0.95; 95% CI, 0.54-1.67). However, females (aOR, 3.01; 95% CI, 1.73-5.34), those 45-64 years (aOR, 2.55; 95% CI, 1.14-6.23), and April-June 2020 enrollees (aOR, 2.39; 95% CI, 1.10-5.19) were more likely to report general symptoms and have poorer PROMIS physical health scores than their respective reference groups. Hispanic participants (difference, -3.05; 95% CI, -5.82 to -0.27) and Black participants (-4.48; 95% CI, -7.94 to -1.02) had poorer PROMIS physical health than White participants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">CCP demonstrated no lasting effect on PASC symptoms or overall health in comparison to the placebo. This study underscores the significance of demographic factors, including sex, age, and timing of acute infection, in influencing symptom reporting 18 months after acute hypoxic COVID-19 hospitalization.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyunah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldfeld</LastName><ForeName>Keith S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Department of Population Health, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobb</LastName><ForeName>Gia F</ForeName><Initials>GF</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturm-Reganato</LastName><ForeName>Caroline L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostrosky-Zeichner</LastName><ForeName>Luis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4784-7589</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayaweera</LastName><ForeName>Dushyantha T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Miami Clinical and Translational Science Institute, University of Miami Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Philley</LastName><ForeName>Julie V</ForeName><Initials>JV</Initials><AffiliationInfo><Affiliation>Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Tyler, UTHealth East Texas, Tyler, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desruisseaux</LastName><ForeName>Mahalia S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Marla J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harold and Muriel Block Institute for Clinical and Translational Research, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochman</LastName><ForeName>Judith S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirofski</LastName><ForeName>Liise-Anne</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-7568-2961</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortigoza</LastName><ForeName>Mila B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0002-9428-1469</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CONTAIN-Extend Study Group </CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001445</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003167</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002556</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002736</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 convalescent plasma</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Patient-Reported Outcomes Measurement Information System</Keyword><Keyword MajorTopicYN="N">acute hypoxic COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. Ostrosky-Zeichner has received research grants and/or personal honoraria for consulting from Pfizer, Gilead Sciences, GlaxoSmithKline, Enanta, Quidel, and Viracor. Jayaweera has received research grants from NIH, Gilead Sciences, ViiV, ST-Pharma, and Janssen Pharmaceuticals. Jayaweera is a Consultant and Scientific Advisory Board Member for GlaxoSmithKline and ViiV pharmaceuticals. All other authors report no potential conflicts.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Hochman</LastName><ForeName>Judith S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cronstein</LastName><ForeName>Bruce N</ForeName><Initials>BN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keeling</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rappoport</LastName><ForeName>Norka</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saraga</LastName><ForeName>Jenna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holahan</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortigoza</LastName><ForeName>Mila B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirofski</LastName><ForeName>Liise-Anne</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyunah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sturm-Reganato</LastName><ForeName>Caroline L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cobb</LastName><ForeName>Gia F</ForeName><Initials>GF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andela</LastName><ForeName>Rakshit</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Darwish</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taveras</LastName><ForeName>Monica R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xin</LastName><ForeName>Patrick S</ForeName><Initials>PS</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaFleur</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleare</LastName><ForeName>Levi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldfeld</LastName><ForeName>Keith S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Yi</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortigoza</LastName><ForeName>Mila B</ForeName><Initials>MB</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Keeffe</LastName><ForeName>Mary L</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cobb</LastName><ForeName>Gia F</ForeName><Initials>GF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sturm-Reganato</LastName><ForeName>Caroline L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahman</LastName><ForeName>Fatema Z</ForeName><Initials>FZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ajayi</LastName><ForeName>Adeyinka O</ForeName><Initials>AO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Sara L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iturrate</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Jacqueline M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ololade E</ForeName><Initials>OE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>Danibel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fong</LastName><ForeName>Charlotte C</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirofski</LastName><ForeName>Liise-Anne</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyunah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keller</LastName><ForeName>Marla J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asencio</LastName><ForeName>Andrea A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eke</LastName><ForeName>Isaiah</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castro</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shan</LastName><ForeName>Jidong</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chalco</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaFleur</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleare</LastName><ForeName>Levi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desruisseaux</LastName><ForeName>Mahalia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cortezzo</LastName><ForeName>Grace M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rocco</LastName><ForeName>Erica</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ndunge</LastName><ForeName>Oscar Bate Akide</ForeName><Initials>OBA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parmelee</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cahil</LastName><ForeName>Staci</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayaweera</LastName><ForeName>Dushyantha T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Chin Chin</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ransford</LastName><ForeName>Daru L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dasmany</LastName><ForeName>Deniz</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corona</LastName><ForeName>Andres</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>Kenia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Gledys L</ForeName><Initials>GL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Otero</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McPherson</LastName><ForeName>David D</ForeName><Initials>DD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostrosky-Zeichner</LastName><ForeName>Luis</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Bela</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nigo</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huebinger</LastName><ForeName>Ryan M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dronavalli</LastName><ForeName>Goutham</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimes</LastName><ForeName>Carolyn Z</ForeName><Initials>CZ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Umana</LastName><ForeName>Virginia E</ForeName><Initials>VE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Maria D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nielsen</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stutz</LastName><ForeName>Taylor P</ForeName><Initials>TP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mammadova</LastName><ForeName>Mehriban</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dentino</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heath</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Jessica G</ForeName><Initials>JG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bello</LastName><ForeName>Fatimah O</ForeName><Initials>FO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinojosa</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Philley</LastName><ForeName>Julie V</ForeName><Initials>JV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devine</LastName><ForeName>Megan S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hibbard</LastName><ForeName>Rebekah L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ford</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>25</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38269049</ArticleId><ArticleId IdType="pmc">PMC10807994</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad686</ArticleId><ArticleId IdType="pii">ofad686</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention. End of the Federal COVID-19 Public Health Emergency (PHE) declaration . Available at: https://www.cdc.gov/coronavirus/2019-ncov/your-health/end-of-phe.html. Accessed June 22, 2023.</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22:e102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Adjaye-Gbewonyo D, Vahratian A, Perrine CG, Bertolli J. Long COVID in adults: United States, 2022. NCHS Data Brief, no 480. Centers for Disease Control and Prevention, National Center for Health Statistics 2023. Available at: 10.15620/cdc:132417. Accessed October 15, 2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.15620/cdc:132417</ArticleId><ArticleId IdType="pubmed">37756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol 2023; 23:618&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. . Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis 2023; 76:e487&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortigoza MB, Yoon H, Goldfeld KS, et al. . Efficacy and safety of COVID-19 convalescent plasma in hospitalized patients: a randomized clinical trial. JAMA Intern Med 2022; 182:115&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8669605</ArticleId><ArticleId IdType="pubmed">34901997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res 2009; 18:873&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2724630</ArticleId><ArticleId IdType="pubmed">19543809</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Cella D, Gershon R, et al. . Representativeness of the Patient-Reported Outcomes Measurement Information System internet panel. J Clin Epidemiol 2010; 63:1169&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943555</ArticleId><ArticleId IdType="pubmed">20688473</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID Infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20:e192&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Casadevall A, Pirofski LA. Misinterpretation of clinical research findings and COVID-19 mortality. Ann Intern Med 2023; 176:993&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10186249</ArticleId><ArticleId IdType="pubmed">37186922</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group . Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397:2049&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121538</ArticleId><ArticleId IdType="pubmed">34000257</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate COVID-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ 2020; 371:m3939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578662</ArticleId><ArticleId IdType="pubmed">33093056</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebo KA, Heath SL, Fukuta Y, et al. . Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio 2023; 14:e0061823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10653913</ArticleId><ArticleId IdType="pubmed">37724870</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post&#x2013;COVID-19 condition. JAMA Intern Med 2023; 183:554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Boglione L, Meli G, Poletti F, et al. . Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect? QJM 2022; 114:865&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690187</ArticleId><ArticleId IdType="pubmed">34850210</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al. . Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis 2023; 23:1119&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevalainen OPO, Horstia S, Laakkonen S, et al. . Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nat Commun 2022; 13:6152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9579198</ArticleId><ArticleId IdType="pubmed">36257950</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J, Padilla S, Fern&#xe1;ndez-Gonz&#xe1;lez M, et al. . Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J Clin Immunol 2021; 41:1490&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X, Cao S, Lee AS, et al. . Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight 2022; 7:e156713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9310538</ArticleId><ArticleId IdType="pubmed">35801588</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman JD, Wang C, Burke JS, et al. . Nucleocapsid-specific antibody function is associated with therapeutic benefit from COVID-19 convalescent plasma therapy. Cell Rep Med 2022; 3:100811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9595358</ArticleId><ArticleId IdType="pubmed">36351430</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Skorniewska Z, Hampshire A, et al. . Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat Med 2023; 29:2498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579097</ArticleId><ArticleId IdType="pubmed">37653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, et al. . Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect 2022; 28:611.e9&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long COVID. Nat Med 2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigfrid L, Drake TM, Pauley E, et al. . Long COVID in adults discharged from UK hospitals after COVID-19: a prospective, multicentre cohort study using the ISARIC WHO clinical characterisation protocol. Lancet Reg Health Eur 2021; 8:100186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343377</ArticleId><ArticleId IdType="pubmed">34386785</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID. National Center for Health Statistics. U.S. Census Bureau, Household Pulse Survey, 2022&#x2013;2023. Available at: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm. Accessed October 22, 2023.</Citation></Reference><Reference><Citation>Zeng F, Dai C, Cai P, et al. . A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex. J Med Virol 2020; 92:2050&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267228</ArticleId><ArticleId IdType="pubmed">32383183</ArticleId></ArticleIdList></Reference><Reference><Citation>Korte W, Buljan M, R&#xf6;sslein M, et al. . SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on. J Infect 2021; 82:e11&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445467</ArticleId><ArticleId IdType="pubmed">32853597</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin EG, Lustig Y, Cohen C, et al. . Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021; 385:e84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Perumal R, Shunmugam L, Naidoo K, et al. . Long COVID: a review and proposed visualization of the complexity of long COVID. Front Immunol 2023; 14:1117464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10157068</ArticleId><ArticleId IdType="pubmed">37153597</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MM, Shamsunder MG, Brazier E, et al. . Racial/ethnic disparities in exposure, disease susceptibility, and clinical outcomes during COVID-19 pandemic in national cohort of adults, United States. Emerg Infect Dis 2022; 28:2171&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9622253</ArticleId><ArticleId IdType="pubmed">36191624</ArticleId></ArticleIdList></Reference><Reference><Citation>Khullar D, Zhang Y, Zang C, et al. . Racial/ethnic disparities in post-acute sequelae of SARS-CoV-2 infection in New York: an EHR-based cohort study from the RECOVER program. J Gen Intern Med 2023; 38:1127&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933823</ArticleId><ArticleId IdType="pubmed">36795327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh R, Ghosh AK, Nyman MA, et al. . PROMIS scales for assessment of persistent post-COVID symptoms: a cross sectional study. J Prim Care Community Health 2021; 12:21501327211030413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8267017</ArticleId><ArticleId IdType="pubmed">34231395</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella D, Riley W, Stone A, et al. . The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005&#x2013;2008. J Clin Epidemiol 2010; 63:1179&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965562</ArticleId><ArticleId IdType="pubmed">20685078</ArticleId></ArticleIdList></Reference><Reference><Citation>Frontera JA, Simon NM. Bridging knowledge gaps in the diagnosis and management of neuropsychiatric sequelae of COVID-19. JAMA Psychiatry 2022; 79:811&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">35767287</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y, Zhao Y-J, Zhang Q-E, et al. . COVID-19-related stigma and its sociodemographic correlates: a comparative study. Global Health 2021; 17:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8103123</ArticleId><ArticleId IdType="pubmed">33962651</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Sillett R, Zhu L, et al. . Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 2022; 9:815&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy BC, Liu Y, Winston-Khan S, Weiner HL, Chitnis T, Glanz BI. Association between PROMIS10, SF-36 and NeuroQoL in persons with multiple sclerosis. Mult Scler Relat Disord 2023; 79:105003.</Citation><ArticleIdList><ArticleId IdType="pubmed">37741027</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L, Tosto-Mancuso J, Wood J, et al. . Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil 2022; 101:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith GJ, Morris TT, Tudball MJ, et al. . Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun 2020; 11:5749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665028</ArticleId><ArticleId IdType="pubmed">33184277</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez-Grande C, Est&#xe9;vez A, Palomino-Cabrera R, et al. . Early SARS-CoV-2 reinfections involving the same or different genomic lineages, Spain. Emerg Infect Dis 2023; 29:1154&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10202887</ArticleId><ArticleId IdType="pubmed">37130503</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Tang P, Coyle P, et al. . Protection against reinfection with the Omicron BA.2.75 subvariant. N Engl J Med 2023; 388:665&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878583</ArticleId><ArticleId IdType="pubmed">36652342</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock MD, Chew RF, Preiss AJ, et al. . Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun 2023; 14:2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard SA, Pollett SD, Fries AC, et al. . Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw Open 2023; 6:e2251360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857077</ArticleId><ArticleId IdType="pubmed">36652247</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: a systematic review and meta-analysis. Vaccine 2023; 41:1783&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC, Oddi A, Peluso MJ, et al. . Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol 2022; 9:221&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Korchut A, Rejdak K. Late neurological consequences of SARS-CoV-2 infection: new challenges for the neurologist. Front Neurosci 2023; 17:1004957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9947479</ArticleId><ArticleId IdType="pubmed">36845421</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. . Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023; 329:1934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. . Distinguishing features of long COVID identified through immune profiling. Nature 2023; 623:139&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisk LE, Gottlieb MA, Spatz ES, et al. . Association of initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw Open 2022; 5:e2244486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9716377</ArticleId><ArticleId IdType="pubmed">36454572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>